Connect (CNTB) Climbs in Active Trading for August 4

Equities Staff  |

Today, Connect Biopharma Holdings Ltd - ADR (NASDAQ:CNTB) was up $0.09 to finish the day Thursday at $1.12.

The company started at $1.05 and shares fluctuated between $1.14 and $1.04 with 186,280 shares trading hands.

Connect is averaging 169,831 shares traded over the last 30 days. They have shed 80.00% YTD.

Connect expects its next earnings on 2022-08-30.

For technical charts, analysis, and more on Connect visit the company profile.

About Connect Biopharma Holdings Ltd - ADR

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).

To get more information on Connect Biopharma Holdings Ltd - ADR and to follow the company's latest updates, you can visit the company's profile page here: Connect Biopharma Holdings Ltd - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content